Etavopivat (FT-4202) is a novel oral activator of PKR that decreases 2,3-DPG levels and hence would increase the HbS O2 affinity to reduce sickling.
FT-4202 increases the hemoglobin S O2 affinity to reduce sickling and improve RBC membrane deformability.
Etavopivat (FT-4202) increased Hb-oxygen affinity and reduced sickling under deoxygenation in ex vivo RBCs from donors with sickle cell disease (SCD).
Oral administration of FT-4202 increases Hb and improves RBC parameters in BERK mice.
Etavopivat is currently being evaluated in clinical trials for the treatment sickle cell disease (SCD).
